U.S. Pharmaceuticals & Biotech Buy the Dip

Teva Pharmaceutical Industries

Market Cap: US$38.4b

Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.

Arrowhead Pharmaceuticals

Market Cap: US$10.8b

Develops medicines for the treatment of intractable diseases in the United States.

ImmunityBio

Market Cap: US$8.6b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Liquidia

Market Cap: US$6.9b

A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.

Twist Bioscience

Market Cap: US$5.6b

Manufactures and sells synthetic DNA-based products.

IDEAYA Biosciences

Market Cap: US$3.5b

A precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Tarsus Pharmaceuticals

Market Cap: US$2.5b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Taysha Gene Therapies

Market Cap: US$2.0b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Stoke Therapeutics

Market Cap: US$2.0b

Engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Capricor Therapeutics

Market Cap: US$1.2b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

MeiraGTx Holdings

Market Cap: US$1.2b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

Solid Biosciences

Market Cap: US$1.0b

Develops therapies for neuromuscular and cardiac diseases in the United States.

REGENXBIO

Market Cap: US$721.2m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

4D Molecular Therapeutics

Market Cap: US$643.5m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Kyverna Therapeutics

Market Cap: US$515.8m

A late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

Sutro Biopharma

Market Cap: US$492.6m

Operates as an oncology company.

Cabaletta Bio

Market Cap: US$485.1m

A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.

Prelude Therapeutics

Market Cap: US$476.5m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

vTv Therapeutics

Market Cap: US$415.6m

A late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.

Century Therapeutics

Market Cap: US$405.8m

A biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

ALX Oncology Holdings

Market Cap: US$285.9m

A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

Nkarta

Market Cap: US$212.5m

A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Canton Strategic Holdings

Market Cap: US$183.6m

Engages in the institutional blockchain adoption and digitization of financial markets in the United States.

OnKure Therapeutics

Market Cap: US$172.9m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.

Oramed Pharmaceuticals

Market Cap: US$165.3m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

iBio

Market Cap: US$75.0m

A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.

Apollomics

Market Cap: US$41.6m

A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.

Polyrizon

Market Cap: US$27.4m

A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.